STEPHANIE RICHARDS: Open Payments
NPI 1245608330 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,533 in 86 payments from 15 companies in 2025. Trend: 2023 $2,134 · 2024 $1,853 · 2025 $1,533
Food & beverage: $1,533
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $269 |
| Novo Nordisk Inc | 16 | $255 |
| AstraZeneca Pharmaceuticals LP | 10 | $224 |
| PFIZER INC. | 10 | $177 |
| Lilly USA, LLC | 10 | $174 |
| Abbott Laboratories | 5 | $130 |
| Gilead Sciences, Inc. | 3 | $81 |
| Dexcom, Inc. | 2 | $51 |
| GlaxoSmithKline, LLC. | 3 | $44 |
| Axsome Therapeutics, Inc. | 1 | $30 |
Products named: MOUNJARO, Wegovy, FREESTYLE LIBRE 3, VRAYLAR, AIRSUPRA, Ozempic, PREVNAR 20, UBRELVY.
Industry payments across TX — which companies pay providers there.
